Investorideas.com - Biotech/Pharma Stock News; UV Flu Technologies (OTCBB: UVFT) Completes Production of "Designing Spaces / Holiday Spaces" TV Segment Featuring ViraTech UV-400 Air Purifier
Broadcast Targets Solution for Indoor Air Quality During Holiday Flu and Cold Season
Share this news:
Subscribe to Investor Ideas Newswire
Visit this company: http://www.uvflutech.com/
CENTERVILLE, MA - October 21, 2010 (Investorideas.com newswire) UV Flu Technologies, Inc. (OTC.BB:UVFT) (the "Company") is pleased to announce that the Company has recently completed taping a segment of the "Designing Spaces" TV Show featuring its flagship ViraTech UV-400 air purification system, which is slated for national broadcast in late November and again in early December. The show, to be aired on the Women's Entertainment channel, focuses on holiday season health issues and is expected to reach up to 75 million households. Exact dates and times will be made available on the Company website shortly.
The theme of the segment is about staying healthy indoors over the holidays, and the UV-400 offers thought-provoking interest for health conscious consumers. The show provides insights into the UV-400's listing as a Medical Device as a result of rigorous laboratory tests which have conclusively proven that the product kills 99% of airborne bacteria in its patented UV chamber. The UV-400 is designed to easily circulate and filter the air within the average home or work environment multiple times per hour, and this will be demonstrated with real life situations and applications during the television presentation.
Given the amount of time people spend indoors during the Holidays, the show notes that not all health issues come as a result of exposure to bacteria. Many volatile compounds are regularly found in furniture, cleaning supplies, building materials, insecticides, and even common household items like hairspray. Poor indoor air quality can lead to increases in allergic reactions and other forms of respiratory problems. The alleviation of these problems will be examined and just how the UV-400 purifies the air of these irritants will be shown.
"We hope to educate people to the many dangers associated with poor indoor air quality, and also that our UV-400 is a very cost-effective way to protect themselves. We believe this show is a tremendous platform to reach one of our key markets: concerned parents who value the health of their families," stated John J. Lennon President of UV Flu Technologies.
Further details regarding the Company's business, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database.
About UV Flu Technologies, Inc. (OTC.BB:UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector. The Company manufactures the ViraTech UV-400, which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria at rates exceeding 99.2% on a first-pass basis. The product also is highly effective in reducing odors and VOC's, or Volatile Organic Compounds, such as acetone, benzene and formaldehyde. ViraTech UV-400 is a Class II medical device and is available without a prescription.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Contact:
Investor Information:
Geaux IR Services, Inc.
Toll-Free: 1-888-355-8838
investors@uvflutech.com
Visit the UVFT showcase profile at http://www.investorideas.com/
and http://www.biotechindustrystocks.com/
Request News and Info on UVFT
Disclosure, Disclaimer/ UVFT is a paid advertising client on Investorideas.com. (showcase biotech stock for one month advertising three thousand)
More Info:
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Thursday, October 21, 2010
Wednesday, October 20, 2010
Investorideas.com - Featured Special Biotech Report; UV Flu Technologies (OTCBB: UVFT), written by Michael Williams at BiotechStockPick.com
Investorideas.com - Featured Special Biotech Report; UV Flu Technologies (OTCBB: UVFT), written by Michael Williams at BiotechStockPick.com
10 reasons to invest in UV Flu Technologies (OTCBB: UVFT)
Point Roberts, WA –October 18, 2010 (Investorideas.com Newswire, www.biotechindustrystocks.com) publishes the following biotech stock report on UV Flu Technologies (OTCBB: UVFT), written by Michael Williams at http://biotechstockpick.com/. Michael Williams is America’s top authority on small-cap biotech stock picks.
Investorideas.com features third party research in multiple industry sectors including biotech. More third party research reports can be found at http://www.investorideas.com/Research/.
Report Excerpt:
Full report at http://biotechstockpick.com and http://www.investorideas.com/Research/
Michael’s latest winning biotech pick is profiled inside this Special Report.
Every few years or so, the “perfect” scenario unfolds for a particular investment. A company may have a great product, for example...and by investing in that company at a time when the market for that product is poised to skyrocket... well, the potential exists for life-altering gains.
My name is Michael Williams, Editor of Market Movers, and it’s my job to uncover those overlooked and potentially “perfect” opportunities and show my readers how to exploit those situations.
Why settle for “boring” 10 - 20% returns?
There’s nothing wrong with earning a 10% or 20% return on a stock, but at Market Movers, modest profits don’t get our blood racing or our pulse pounding.
My subscribers and I are addicted to the thrill of home runs: buying a small, undiscovered company and watching its share price go through the roof! That’s why I think you will be interested in reading more about my current pick, UV Flu Technologies (UVFT), an emerging company that is about to become a major player in the biotech industry.
How do you separate the winners from the losers with biotech stocks? By remembering that winners outperform the market for five very specific reasons.
IT’S NEVER ACCIDENTAL.
Leadership.
We look at a company’s leadership. Are they experienced and have they proven their skills at other companies?
Earnings.
Are their future earnings robust, yet currently priced well below (up to 80%) their fair value?
Most of our stocks are either selling at a deep discount to their net current asset value, or their P/E is reasonably priced within the average range for their sector.
Business Plan.
Do they have a sound business plan? Without the right directions you can never get to where you’re going.
Market Trends.
Out of the few companies that get this far our team then looks over current political, economic and investment trends to make our final recommendations. Social, political and economic trends must be moving in the right direction. Investors must be confident that prices will be heading up, and as the enclosed report details, biotech has never been hotter - and demand is expected to continue soaring!
Investor Awareness.
Furthermore, ‘hot’ stocks are almost always actively marketed to investors - and everyone benefits because shares are like products: THEY MUST BE SOLD. Every biotech company should meet this standard - five out of five, nothing less. If a company is weak in even one area, it won’t make my pick list.
As you’ll see from the attached special report, UV Flu Technologies has a great story to tell - one of the best opportunities to come along in years, as a matter of fact - and they’ll be very aggressive in making sure it gets wide distribution. (After all, what good is an up-and-coming investment if hardly anyone hears about it?!!)
I’d urge you to take a few minutes to learn more about this company, and further investigate its prospects with your broker or investment advisor.
10 reasons to invest in UVFT
…for what could be the killer biotech buy of the year with 370% profit potential!
1. FDA approval has already been received, allowing UVFT to market its product as a medical device—such approval is highly unusual for a biotech at this stage. Not to mention very few air purifiers have FDA approval. That gives UVFT a big competitive edge.
2. Top 5 U.S. Hospitals Put UVFT Technology to Work—UVFT’s UV-400 is already in operation at two of the most respected medical institutions: The Division of Infectious Diseases at Massachusetts General Hospital and New England Baptist Hospital.
3. Independent laboratory testing proves UVFT’s technology works and is 99.2% to 99.9% effective at killing bacteria on the first pass.
4. OSHA, the main U.S. federal agency charged with the enforcement of safety and health legislation, is creating a moneymaking opportunity for UVFT and its shareholders. Indoor air quality is a growing problem, creating health hazards and sick buildings. OSHA is already issuing directives to provide a healthier work environment for workers.
5. This year’s bad flu season is all it will take to send UVFT’s share price soaring to potential highs of 370% or higher. Business and consumers are going to want the best protection available—and it won’t be blue masks.
6. Strong buyout potential by corporate giants 3M or Honeywell that could send share prices through the rafters.
7. Shares at the ground floor entry point of just $0.30— this is the stage you stand to make the biggest gains—this low price still has blue sky potential.
8. Experienced management team—a powerhouse team that’s been with the heavyweights in health care and finance—those such as Johnson and Johnson and Janney Montgomery Scott. One key team member already successfully brought a $20 million per year product to market! Now UVFT is about to do it again. see pg. 10
9. THREE revenue streams already in place: the flagship Viratech UV-400, the smaller version of the UV-400, and replaceable cartridges for the units are all avenues for UVFT to generate a steady revenue stream.
10. UVFT has the first breakthrough in the air purification market in 70 years. Breakthroughs like that create investment opportunities of a lifetime.
Dying for an Answer
Hospital infections kill more people each year than AIDS, breast cancer and auto accidents combined
Next time you check into the hospital you’re going to think twice. What used to be a safe haven for people to get well has virtually become a death sentence. As many as 1 in 10 patients that checks into a U.S. hospital acquires an infection. Nearly 2 million patients a year are infected. What’s worse…
100,000 WILL DIE
As if the toll on human lives was not enough, the costs associated with hospital-acquired bacterial infections are staggering.
The Wall Street Journal reports that hospital acquired infections cost up to $6.5 BILLION a year. What’s more, these highly preventable bacterial infections cost the U.S. about $30 billion a year, according to the Center for Disease Control and Prevention.
Bacterial infections acquired during hospital stays are so widespread that 26 states have enacted laws requiring hospitals to report their infection rates.
STAPH (MRSA) Infections could propel UVFT to Super Stock Status
In 1993, fewer than 2,000 people in U.S. hospitals would contract a staph infection. By 2005, that number rose to 368,000 and in 2007 staph infections claimed 880,000 victims.
A recent nationwide study showed that patients with staph infections incur hospital costs that are more than triple the average hospital costs of other patients.
MRSA is certainly not the only bacterial infection making us sick and killing us. There are post-surgical wound infections, urinary tract infections, C. Difficile, influenza, pneumonia—the list goes on and on.
Our hospitals want a device that wipes out and kills these harmful bacteria and they will pay to get it. UVFT has the next generation—a revolution in air purification and health care that could dramatically improve every U.S. hospitals bottomline and our health.
Using UVFT’s FDA-approved Viratech UV-400, hospitals can begin obliterating bacteria and airborne pathogens on-the-spot with a 99% kill rate on every pass through. I have not come across even one other product that remotely comes close.
Buy up as many shares of UVFT as you can then sit back and watch it rocket from $0.30 to $0.92 then $1.41 inside of 12 months.
Environmental Protection Agency Warns:
“Indoor air quality poses a greater threat than outdoor air”
________________________________________
Take a look at the rise of chronic respiratory diseases like asthma, for example, and it’s easy to understand why the EPA has proclaimed indoor air quality a major threat.
In 1990, there were 10 million Americans suffering with asthma. Today that number stands at an eye-popping 20 million—DOUBLE in the past 20 years. What’s worse, asthma is projected to DOUBLE again over the next 20 years.
What’s suffocating our ability to breathe free and clear? Bacteria, molds and toxins as well as exposure to chemicals in cleaning agents, pollution, second hand smoke and more—all free floating through the air with nothing to stop them.
UVFT scientists, researchers and engineers saw a tremendous market opportunity to develop an air purification system that would not filter these poisons and toxins but eradicate them—kill them dead.
Indoor air quality is so poor that OSHA is Stepping In.
When the Occupational Safety and Health Administration steps in, businesses like UVFT stand to make a lot of money
While OSHA has not yet called for a formal regulation, it is in the process of calling for new standards in airborne infectious disease protection for health care workers. OSHA’s recent enforcement directive requires that health care employers protect workers from tuberculosis, SARS, H1N1 and other influenza.
For shareholders in UVFT this is huge news. Anytime OSHA issues a directive or anytime a new federal regulation is passed, that spells a tremendous moneymaking opportunity for companies that have to provide products and services to companies that must comply—and for its investors.
Using UVFT’s breakthrough Viratech UV-400 the millions of workplaces and sick buildings around the country can better protect their workers—and their bottomline—from airborne infectious diseases and bacteria.
I’m convinced that UVFT is the next Big Money Winner
And then... there’s the flu
Remember the H1N1 pandemic last year? A staggering $1 BILLION was spent on H1N1 vaccine development with $4.3 BILLION spent on the response. Who could forget the fear over Avian (Bird) Flu or SARS a few years ago? Even seasonal flu kills.
Put it altogether and think of the potential for UVFT’s technology to revolutionize the industry. Influenza, bacterial infections, chronic respiratory diseases—the market for UVFT technology is mind boggling.
To read full article please check out http://biotechstockpick.com/
The research report is the content and opinion of Michael Williams at BiotechStockPick.com.
UV Flu Technologies (OTCBB: UVFT) is a showcase biotech stock on Investorideas.com (please read disclosure and disclaimers)
Visit the showcase page on Investorideas.com
http://www.investorideas.com/CO/UVFT/
Request info :
http://www.investorideas.com/Resources/Newsletter.asp
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including mining and gold stocks, in addition to global markets including China, India, the Middle East and Australia. Investorideas.com is known for its comprehensive stock directories in each sector and sector specific newswires.
About our Biotech investor portal: www.biotechindustrystocks.com
BiotechIndustryStocks.com is a global meeting place for investors and industry following the sector, within Investorideas.com. Global visitors use the site daily to research the latest news, articles, audio, research reports and our stock directories.
Disclaimer: The following news is paid for by third party on behalf of UV Flu Technologies, Inc., (three thousand per month) Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
C Van Zant: 800-665-0411 - cvanzant@investorideas.com
Source - Investorideas.com
10 reasons to invest in UV Flu Technologies (OTCBB: UVFT)
Point Roberts, WA –October 18, 2010 (Investorideas.com Newswire, www.biotechindustrystocks.com) publishes the following biotech stock report on UV Flu Technologies (OTCBB: UVFT), written by Michael Williams at http://biotechstockpick.com/. Michael Williams is America’s top authority on small-cap biotech stock picks.
Investorideas.com features third party research in multiple industry sectors including biotech. More third party research reports can be found at http://www.investorideas.com/Research/.
Report Excerpt:
Full report at http://biotechstockpick.com and http://www.investorideas.com/Research/
Michael’s latest winning biotech pick is profiled inside this Special Report.
Every few years or so, the “perfect” scenario unfolds for a particular investment. A company may have a great product, for example...and by investing in that company at a time when the market for that product is poised to skyrocket... well, the potential exists for life-altering gains.
My name is Michael Williams, Editor of Market Movers, and it’s my job to uncover those overlooked and potentially “perfect” opportunities and show my readers how to exploit those situations.
Why settle for “boring” 10 - 20% returns?
There’s nothing wrong with earning a 10% or 20% return on a stock, but at Market Movers, modest profits don’t get our blood racing or our pulse pounding.
My subscribers and I are addicted to the thrill of home runs: buying a small, undiscovered company and watching its share price go through the roof! That’s why I think you will be interested in reading more about my current pick, UV Flu Technologies (UVFT), an emerging company that is about to become a major player in the biotech industry.
How do you separate the winners from the losers with biotech stocks? By remembering that winners outperform the market for five very specific reasons.
IT’S NEVER ACCIDENTAL.
Leadership.
We look at a company’s leadership. Are they experienced and have they proven their skills at other companies?
Earnings.
Are their future earnings robust, yet currently priced well below (up to 80%) their fair value?
Most of our stocks are either selling at a deep discount to their net current asset value, or their P/E is reasonably priced within the average range for their sector.
Business Plan.
Do they have a sound business plan? Without the right directions you can never get to where you’re going.
Market Trends.
Out of the few companies that get this far our team then looks over current political, economic and investment trends to make our final recommendations. Social, political and economic trends must be moving in the right direction. Investors must be confident that prices will be heading up, and as the enclosed report details, biotech has never been hotter - and demand is expected to continue soaring!
Investor Awareness.
Furthermore, ‘hot’ stocks are almost always actively marketed to investors - and everyone benefits because shares are like products: THEY MUST BE SOLD. Every biotech company should meet this standard - five out of five, nothing less. If a company is weak in even one area, it won’t make my pick list.
As you’ll see from the attached special report, UV Flu Technologies has a great story to tell - one of the best opportunities to come along in years, as a matter of fact - and they’ll be very aggressive in making sure it gets wide distribution. (After all, what good is an up-and-coming investment if hardly anyone hears about it?!!)
I’d urge you to take a few minutes to learn more about this company, and further investigate its prospects with your broker or investment advisor.
10 reasons to invest in UVFT
…for what could be the killer biotech buy of the year with 370% profit potential!
1. FDA approval has already been received, allowing UVFT to market its product as a medical device—such approval is highly unusual for a biotech at this stage. Not to mention very few air purifiers have FDA approval. That gives UVFT a big competitive edge.
2. Top 5 U.S. Hospitals Put UVFT Technology to Work—UVFT’s UV-400 is already in operation at two of the most respected medical institutions: The Division of Infectious Diseases at Massachusetts General Hospital and New England Baptist Hospital.
3. Independent laboratory testing proves UVFT’s technology works and is 99.2% to 99.9% effective at killing bacteria on the first pass.
4. OSHA, the main U.S. federal agency charged with the enforcement of safety and health legislation, is creating a moneymaking opportunity for UVFT and its shareholders. Indoor air quality is a growing problem, creating health hazards and sick buildings. OSHA is already issuing directives to provide a healthier work environment for workers.
5. This year’s bad flu season is all it will take to send UVFT’s share price soaring to potential highs of 370% or higher. Business and consumers are going to want the best protection available—and it won’t be blue masks.
6. Strong buyout potential by corporate giants 3M or Honeywell that could send share prices through the rafters.
7. Shares at the ground floor entry point of just $0.30— this is the stage you stand to make the biggest gains—this low price still has blue sky potential.
8. Experienced management team—a powerhouse team that’s been with the heavyweights in health care and finance—those such as Johnson and Johnson and Janney Montgomery Scott. One key team member already successfully brought a $20 million per year product to market! Now UVFT is about to do it again. see pg. 10
9. THREE revenue streams already in place: the flagship Viratech UV-400, the smaller version of the UV-400, and replaceable cartridges for the units are all avenues for UVFT to generate a steady revenue stream.
10. UVFT has the first breakthrough in the air purification market in 70 years. Breakthroughs like that create investment opportunities of a lifetime.
Dying for an Answer
Hospital infections kill more people each year than AIDS, breast cancer and auto accidents combined
Next time you check into the hospital you’re going to think twice. What used to be a safe haven for people to get well has virtually become a death sentence. As many as 1 in 10 patients that checks into a U.S. hospital acquires an infection. Nearly 2 million patients a year are infected. What’s worse…
100,000 WILL DIE
As if the toll on human lives was not enough, the costs associated with hospital-acquired bacterial infections are staggering.
The Wall Street Journal reports that hospital acquired infections cost up to $6.5 BILLION a year. What’s more, these highly preventable bacterial infections cost the U.S. about $30 billion a year, according to the Center for Disease Control and Prevention.
Bacterial infections acquired during hospital stays are so widespread that 26 states have enacted laws requiring hospitals to report their infection rates.
STAPH (MRSA) Infections could propel UVFT to Super Stock Status
In 1993, fewer than 2,000 people in U.S. hospitals would contract a staph infection. By 2005, that number rose to 368,000 and in 2007 staph infections claimed 880,000 victims.
A recent nationwide study showed that patients with staph infections incur hospital costs that are more than triple the average hospital costs of other patients.
MRSA is certainly not the only bacterial infection making us sick and killing us. There are post-surgical wound infections, urinary tract infections, C. Difficile, influenza, pneumonia—the list goes on and on.
Our hospitals want a device that wipes out and kills these harmful bacteria and they will pay to get it. UVFT has the next generation—a revolution in air purification and health care that could dramatically improve every U.S. hospitals bottomline and our health.
Using UVFT’s FDA-approved Viratech UV-400, hospitals can begin obliterating bacteria and airborne pathogens on-the-spot with a 99% kill rate on every pass through. I have not come across even one other product that remotely comes close.
Buy up as many shares of UVFT as you can then sit back and watch it rocket from $0.30 to $0.92 then $1.41 inside of 12 months.
Environmental Protection Agency Warns:
“Indoor air quality poses a greater threat than outdoor air”
________________________________________
Take a look at the rise of chronic respiratory diseases like asthma, for example, and it’s easy to understand why the EPA has proclaimed indoor air quality a major threat.
In 1990, there were 10 million Americans suffering with asthma. Today that number stands at an eye-popping 20 million—DOUBLE in the past 20 years. What’s worse, asthma is projected to DOUBLE again over the next 20 years.
What’s suffocating our ability to breathe free and clear? Bacteria, molds and toxins as well as exposure to chemicals in cleaning agents, pollution, second hand smoke and more—all free floating through the air with nothing to stop them.
UVFT scientists, researchers and engineers saw a tremendous market opportunity to develop an air purification system that would not filter these poisons and toxins but eradicate them—kill them dead.
Indoor air quality is so poor that OSHA is Stepping In.
When the Occupational Safety and Health Administration steps in, businesses like UVFT stand to make a lot of money
While OSHA has not yet called for a formal regulation, it is in the process of calling for new standards in airborne infectious disease protection for health care workers. OSHA’s recent enforcement directive requires that health care employers protect workers from tuberculosis, SARS, H1N1 and other influenza.
For shareholders in UVFT this is huge news. Anytime OSHA issues a directive or anytime a new federal regulation is passed, that spells a tremendous moneymaking opportunity for companies that have to provide products and services to companies that must comply—and for its investors.
Using UVFT’s breakthrough Viratech UV-400 the millions of workplaces and sick buildings around the country can better protect their workers—and their bottomline—from airborne infectious diseases and bacteria.
I’m convinced that UVFT is the next Big Money Winner
And then... there’s the flu
Remember the H1N1 pandemic last year? A staggering $1 BILLION was spent on H1N1 vaccine development with $4.3 BILLION spent on the response. Who could forget the fear over Avian (Bird) Flu or SARS a few years ago? Even seasonal flu kills.
Put it altogether and think of the potential for UVFT’s technology to revolutionize the industry. Influenza, bacterial infections, chronic respiratory diseases—the market for UVFT technology is mind boggling.
To read full article please check out http://biotechstockpick.com/
The research report is the content and opinion of Michael Williams at BiotechStockPick.com.
UV Flu Technologies (OTCBB: UVFT) is a showcase biotech stock on Investorideas.com (please read disclosure and disclaimers)
Visit the showcase page on Investorideas.com
http://www.investorideas.com/CO/UVFT/
Request info :
http://www.investorideas.com/Resources/Newsletter.asp
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including mining and gold stocks, in addition to global markets including China, India, the Middle East and Australia. Investorideas.com is known for its comprehensive stock directories in each sector and sector specific newswires.
About our Biotech investor portal: www.biotechindustrystocks.com
BiotechIndustryStocks.com is a global meeting place for investors and industry following the sector, within Investorideas.com. Global visitors use the site daily to research the latest news, articles, audio, research reports and our stock directories.
Disclaimer: The following news is paid for by third party on behalf of UV Flu Technologies, Inc., (three thousand per month) Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
C Van Zant: 800-665-0411 - cvanzant@investorideas.com
Source - Investorideas.com
Tuesday, October 19, 2010
Investorideas.com - Biotechnology Stocks; UV Flu Technologies (OTCBB: UVFT) UV-400 Air Purifier Chosen by XV Beacon Hotel
Investorideas.com - Biotechnology Stocks; UV Flu Technologies (OTCBB: UVFT) UV-400 Air Purifier Chosen by XV Beacon Hotel
UV-400 Air Purifier Selected for new Hypo-Allergenic Program as Health Oriented Enhancement
Category: Investment, Biotech
Visit this company: http://www.uvflutech.com/
CENTERVILLE, MA - October 19, 2010 (Investorideas.com newswire, http://www.biotechindustrystocks.com/) Biotechnology Stock News; UV Flu Technologies, Inc. (OTC.BB:UVFT) reports the Boston's XV Beacon Hotel has chosen the UV-400 bacteria killing air purifier as an added value offering to their guests as a health oriented enhancement available at their multi award winning prestige property.
The XV Beacon Hotel (www.xvbeacon.com) is a 2010 recipient of a Condé Nast award of excellence, and was ranked in 2009 as "#4 Top 20 Business Hotel in the World" by Travel & Leisure Magazine, and "#5 World's Best Small Hotel: US and Canada" by Travel & Leisure Magazine, alongside numerous awards from industry leading advisors such as Fodor's, Forbes Traveller, American Express and many others.
Hotel management noted that, "Cold and flu season may be coming on strong, but for allergy sufferers the battle against sniffles and watery eyes never ends. Now XV Beacon in Boston is taking up arms for severely allergic guests with NEW Hypo-Allergenic Guest Rooms courtesy of the ViraTech UV-400 advanced air purification system. This is just the latest example of how the award-winning boutique hotel on Beacon Hill puts the comfort of its guests above everything else."
The ViraTech UV-400 is a breath of fresh air for severely allergic guests. Approved by Edison Testing Laboratories and certified as a medical device by the FDA, the otherwise inconspicuous air filter kills more than 99% of indoor airborne bacteria while significantly reducing sinus-irritating particles and odors.
The XV Beacon plans to employ the ViraTech UV-400 upon request to "prep" guest rooms for a one-hour period prior to arrival on a complimentary basis and for a small fee will make the unit available for continuous use to ensure their room remains nearly allergen-free throughout their entire stay.
UV Flu Technologies Company President & CEO John J. Lennon stated, "As we head toward the time of year where holiday travel plans coincide with the onset of flu and cold season, the efficacy of our product can offer concerned hotel guests newer, healthier choices never before available when it comes to making their accommodation plans. We are thrilled that such a well-regarded property as the XV Beacon has the vision and leadership to see the potential benefits our product can provide their guests both at this time of year, but especially for allergy sufferers year round. We anticipate this market segment to grow exponentially as other properties grasp the significance of this new technology as we head towards 2011."
Further details regarding the Company's business, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database.
About UV Flu Technologies, Inc. (OTC.BB:UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector. The Company manufactures the ViraTech UV-400, which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria at rates exceeding 99.2% on a first-pass basis. The product also is highly effective in reducing odors and VOC's, or Volatile Organic Compounds, such as acetone, benzene and formaldehyde. ViraTech UV-400 is a Class II medical device and is available without a prescription.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Contact:
Investor Information:
Geaux IR Services, Inc.
Toll-Free: 1-888-355-8838
investors@uvflutech.com
Visit the UVFT showcase profile at Investorideas.com
Request News and Info on UVFT
Disclosure, Disclaimer/ UVFT is a paid advertising client on Investorideas.com. (showcase biotech stock for one month advertising three thousand)
More Info:
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
More Info:
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
UV-400 Air Purifier Selected for new Hypo-Allergenic Program as Health Oriented Enhancement
Category: Investment, Biotech
Visit this company: http://www.uvflutech.com/
CENTERVILLE, MA - October 19, 2010 (Investorideas.com newswire, http://www.biotechindustrystocks.com/) Biotechnology Stock News; UV Flu Technologies, Inc. (OTC.BB:UVFT) reports the Boston's XV Beacon Hotel has chosen the UV-400 bacteria killing air purifier as an added value offering to their guests as a health oriented enhancement available at their multi award winning prestige property.
The XV Beacon Hotel (www.xvbeacon.com) is a 2010 recipient of a Condé Nast award of excellence, and was ranked in 2009 as "#4 Top 20 Business Hotel in the World" by Travel & Leisure Magazine, and "#5 World's Best Small Hotel: US and Canada" by Travel & Leisure Magazine, alongside numerous awards from industry leading advisors such as Fodor's, Forbes Traveller, American Express and many others.
Hotel management noted that, "Cold and flu season may be coming on strong, but for allergy sufferers the battle against sniffles and watery eyes never ends. Now XV Beacon in Boston is taking up arms for severely allergic guests with NEW Hypo-Allergenic Guest Rooms courtesy of the ViraTech UV-400 advanced air purification system. This is just the latest example of how the award-winning boutique hotel on Beacon Hill puts the comfort of its guests above everything else."
The ViraTech UV-400 is a breath of fresh air for severely allergic guests. Approved by Edison Testing Laboratories and certified as a medical device by the FDA, the otherwise inconspicuous air filter kills more than 99% of indoor airborne bacteria while significantly reducing sinus-irritating particles and odors.
The XV Beacon plans to employ the ViraTech UV-400 upon request to "prep" guest rooms for a one-hour period prior to arrival on a complimentary basis and for a small fee will make the unit available for continuous use to ensure their room remains nearly allergen-free throughout their entire stay.
UV Flu Technologies Company President & CEO John J. Lennon stated, "As we head toward the time of year where holiday travel plans coincide with the onset of flu and cold season, the efficacy of our product can offer concerned hotel guests newer, healthier choices never before available when it comes to making their accommodation plans. We are thrilled that such a well-regarded property as the XV Beacon has the vision and leadership to see the potential benefits our product can provide their guests both at this time of year, but especially for allergy sufferers year round. We anticipate this market segment to grow exponentially as other properties grasp the significance of this new technology as we head towards 2011."
Further details regarding the Company's business, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database.
About UV Flu Technologies, Inc. (OTC.BB:UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector. The Company manufactures the ViraTech UV-400, which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria at rates exceeding 99.2% on a first-pass basis. The product also is highly effective in reducing odors and VOC's, or Volatile Organic Compounds, such as acetone, benzene and formaldehyde. ViraTech UV-400 is a Class II medical device and is available without a prescription.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Contact:
Investor Information:
Geaux IR Services, Inc.
Toll-Free: 1-888-355-8838
investors@uvflutech.com
Visit the UVFT showcase profile at Investorideas.com
Request News and Info on UVFT
Disclosure, Disclaimer/ UVFT is a paid advertising client on Investorideas.com. (showcase biotech stock for one month advertising three thousand)
More Info:
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
More Info:
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Investorideas.com - Biotech/Pharma Stock News; UV Flu Technologies (OTCBB: UVFT) Selected by Award Winning Hotel to Provide UV-400 Air Purifier to Launch NEW Hypo-Allergenic Guest Room Program
Investorideas.com - Biotech/Pharma Stock News; UV Flu Technologies (OTCBB: UVFT) Selected by Award Winning Hotel to Provide UV-400 Air Purifier to Launch NEW Hypo-Allergenic Guest Room Program
Visit this company: http://www.uvflutech.com/
CENTERVILLE, MA - October 19, 2010 (Investorideas.com newswire) UV Flu Technologies, Inc. (OTC.BB:UVFT) (the "Company") is pleased to announce that Boston's XV Beacon Hotel has selected the UV-400 bacteria killing air purifier as an added value offering to their guests as a health oriented enhancement available at their multi award winning prestige property.
The XV Beacon Hotel (www.xvbeacon.com) is a 2010 recipient of a Condé Nast award of excellence, and was ranked in 2009 as "#4 Top 20 Business Hotel in the World" by Travel & Leisure Magazine, and "#5 World's Best Small Hotel: US and Canada" by Travel & Leisure Magazine, alongside numerous awards from industry leading advisors such as Fodor's, Forbes Traveller, American Express and many others.
Hotel management noted that, "Cold and flu season may be coming on strong, but for allergy sufferers the battle against sniffles and watery eyes never ends. Now XV Beacon in Boston is taking up arms for severely allergic guests with NEW Hypo-Allergenic Guest Rooms courtesy of the ViraTech UV-400 advanced air purification system. This is just the latest example of how the award-winning boutique hotel on Beacon Hill puts the comfort of its guests above everything else."
The ViraTech UV-400 is a breath of fresh air for severely allergic guests. Approved by Edison Testing Laboratories and certified as a medical device by the FDA, the otherwise inconspicuous air filter kills more than 99% of indoor airborne bacteria while significantly reducing sinus-irritating particles and odors.
The XV Beacon plans to employ the ViraTech UV-400 upon request to "prep" guest rooms for a one-hour period prior to arrival on a complimentary basis and for a small fee will make the unit available for continuous use to ensure their room remains nearly allergen-free throughout their entire stay.
UV Flu Technologies Company President & CEO John J. Lennon stated, "As we head toward the time of year where holiday travel plans coincide with the onset of flu and cold season, the efficacy of our product can offer concerned hotel guests newer, healthier choices never before available when it comes to making their accommodation plans. We are thrilled that such a well-regarded property as the XV Beacon has the vision and leadership to see the potential benefits our product can provide their guests both at this time of year, but especially for allergy sufferers year round. We anticipate this market segment to grow exponentially as other properties grasp the significance of this new technology as we head towards 2011."
Further details regarding the Company's business, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database.
About UV Flu Technologies, Inc. (OTC.BB:UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector. The Company manufactures the ViraTech UV-400, which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria at rates exceeding 99.2% on a first-pass basis. The product also is highly effective in reducing odors and VOC's, or Volatile Organic Compounds, such as acetone, benzene and formaldehyde. ViraTech UV-400 is a Class II medical device and is available without a prescription.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Contact:
Investor Information:
Geaux IR Services, Inc.
Toll-Free: 1-888-355-8838
investors@uvflutech.com
Visit the UVFT showcase profile at Investorideas.com
Request News and Info on UVFT
Disclosure, Disclaimer/ UVFT is a paid advertising client on Investorideas.com ( showcase biotech stock three thousand )
More Info:
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Visit this company: http://www.uvflutech.com/
CENTERVILLE, MA - October 19, 2010 (Investorideas.com newswire) UV Flu Technologies, Inc. (OTC.BB:UVFT) (the "Company") is pleased to announce that Boston's XV Beacon Hotel has selected the UV-400 bacteria killing air purifier as an added value offering to their guests as a health oriented enhancement available at their multi award winning prestige property.
The XV Beacon Hotel (www.xvbeacon.com) is a 2010 recipient of a Condé Nast award of excellence, and was ranked in 2009 as "#4 Top 20 Business Hotel in the World" by Travel & Leisure Magazine, and "#5 World's Best Small Hotel: US and Canada" by Travel & Leisure Magazine, alongside numerous awards from industry leading advisors such as Fodor's, Forbes Traveller, American Express and many others.
Hotel management noted that, "Cold and flu season may be coming on strong, but for allergy sufferers the battle against sniffles and watery eyes never ends. Now XV Beacon in Boston is taking up arms for severely allergic guests with NEW Hypo-Allergenic Guest Rooms courtesy of the ViraTech UV-400 advanced air purification system. This is just the latest example of how the award-winning boutique hotel on Beacon Hill puts the comfort of its guests above everything else."
The ViraTech UV-400 is a breath of fresh air for severely allergic guests. Approved by Edison Testing Laboratories and certified as a medical device by the FDA, the otherwise inconspicuous air filter kills more than 99% of indoor airborne bacteria while significantly reducing sinus-irritating particles and odors.
The XV Beacon plans to employ the ViraTech UV-400 upon request to "prep" guest rooms for a one-hour period prior to arrival on a complimentary basis and for a small fee will make the unit available for continuous use to ensure their room remains nearly allergen-free throughout their entire stay.
UV Flu Technologies Company President & CEO John J. Lennon stated, "As we head toward the time of year where holiday travel plans coincide with the onset of flu and cold season, the efficacy of our product can offer concerned hotel guests newer, healthier choices never before available when it comes to making their accommodation plans. We are thrilled that such a well-regarded property as the XV Beacon has the vision and leadership to see the potential benefits our product can provide their guests both at this time of year, but especially for allergy sufferers year round. We anticipate this market segment to grow exponentially as other properties grasp the significance of this new technology as we head towards 2011."
Further details regarding the Company's business, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database.
About UV Flu Technologies, Inc. (OTC.BB:UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector. The Company manufactures the ViraTech UV-400, which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria at rates exceeding 99.2% on a first-pass basis. The product also is highly effective in reducing odors and VOC's, or Volatile Organic Compounds, such as acetone, benzene and formaldehyde. ViraTech UV-400 is a Class II medical device and is available without a prescription.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Contact:
Investor Information:
Geaux IR Services, Inc.
Toll-Free: 1-888-355-8838
investors@uvflutech.com
Visit the UVFT showcase profile at Investorideas.com
Request News and Info on UVFT
Disclosure, Disclaimer/ UVFT is a paid advertising client on Investorideas.com ( showcase biotech stock three thousand )
More Info:
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Monday, October 18, 2010
Investorideas.com - Today's Biotech News: UV Flu Technologies (OTCBB: UVFT) Air Purification Medical Device, Selected for Second Profile in UK-Based "Public Service Review"
Investorideas.com - Today's Biotech News: UV Flu Technologies (OTCBB: UVFT) Air Purification Medical Device, Selected for Second Profile in UK-Based "Public Service Review"
"The spread of airborne bacteria and infectious diseases in the United Kingdom, in some areas, is reaching epidemic levels," - Jack Lennon, President of UV Flu Technologies.
CENTERVILLE, MA – October 18, 2010 (InvestorIdeas.com Newswire, www.biotechindustrystocks.com) – Biotech Stock News- UV Flu Technologies, Inc. (OTCBB: UVFT) reports it has been selected as the only air purification medical device to be listed in the Infection Control Segment of the prestigious UK-based opinion and analysis industry publication "Public Service Review." In this, our second appearance for 2010, the Company offers an informative profile within the magazine as well as a full page back cover advertisement.
The Public Service Review features contributors that include UK and foreign ministers, senior civil servants, experts and academics discussing the latest initiatives and projects along with case studies and comments on best practices affecting public sector initiatives worldwide.
"The spread of airborne bacteria and infectious diseases in the United Kingdom, in some areas, is reaching epidemic levels," said Jack Lennon, President of UV Flu Technologies. "There is more than a 10% risk of becoming infected by HAI's, or hospital associated infections, in many of the medical facilities in the United Kingdom, making Infection Control a much more visible issue than it is in this country. Being selected for inclusion by the "Review" as the only laboratory tested device capable of killing these bacterial superbugs is a distinct honor."
Mr. Lennon continued to say, "There is a great deal of attention in the UK, and in the United States, on the spread of MRSA, a bacteria resistant to antibiotics and estimated to kill tens of thousands of people every year, in many instances affects people who have been in a medical facility. In fact, over the last 4 weeks an outbreak of Legionnaires Disease in South Wales garnered international attention as three deaths were reported, and a number of people were stricken. The world believed Legionnaires to no longer pose a threat, but experts believe it kills thousands of people yearly through improper diagnosis as pneumonia. The ViraTech UV- 400 cost effectively and efficiently kills these airborne bacterial strains, and it was this that led to our inclusion in this particular issue."
Further details regarding the Company's business, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database.
About UV Flu Technologies, Inc. (OTCBB: UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector. The Company manufactures the ViraTech UV-400, which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria at rates exceeding 99.2% on a first-pass basis. The product also is highly effective in reducing odors and VOC's, or Volatile Organic Compounds, such as acetone, benzene and formaldehyde. ViraTech UV-400 is a Class II medical device and is available without a prescription.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Investor Information:
Geaux IR Services, Inc.Toll-Free: 1-888-355-8838investors@uvflutech.com
SOURCE: UV Flu Technologies, Inc.
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Connect with Investorideas.com - http://www.twitter.com/Investorideas Publish Your News - Send a release - http://www.investorideas.com/News-Upload/
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.aspInvestorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
"The spread of airborne bacteria and infectious diseases in the United Kingdom, in some areas, is reaching epidemic levels," - Jack Lennon, President of UV Flu Technologies.
CENTERVILLE, MA – October 18, 2010 (InvestorIdeas.com Newswire, www.biotechindustrystocks.com) – Biotech Stock News- UV Flu Technologies, Inc. (OTCBB: UVFT) reports it has been selected as the only air purification medical device to be listed in the Infection Control Segment of the prestigious UK-based opinion and analysis industry publication "Public Service Review." In this, our second appearance for 2010, the Company offers an informative profile within the magazine as well as a full page back cover advertisement.
The Public Service Review features contributors that include UK and foreign ministers, senior civil servants, experts and academics discussing the latest initiatives and projects along with case studies and comments on best practices affecting public sector initiatives worldwide.
"The spread of airborne bacteria and infectious diseases in the United Kingdom, in some areas, is reaching epidemic levels," said Jack Lennon, President of UV Flu Technologies. "There is more than a 10% risk of becoming infected by HAI's, or hospital associated infections, in many of the medical facilities in the United Kingdom, making Infection Control a much more visible issue than it is in this country. Being selected for inclusion by the "Review" as the only laboratory tested device capable of killing these bacterial superbugs is a distinct honor."
Mr. Lennon continued to say, "There is a great deal of attention in the UK, and in the United States, on the spread of MRSA, a bacteria resistant to antibiotics and estimated to kill tens of thousands of people every year, in many instances affects people who have been in a medical facility. In fact, over the last 4 weeks an outbreak of Legionnaires Disease in South Wales garnered international attention as three deaths were reported, and a number of people were stricken. The world believed Legionnaires to no longer pose a threat, but experts believe it kills thousands of people yearly through improper diagnosis as pneumonia. The ViraTech UV- 400 cost effectively and efficiently kills these airborne bacterial strains, and it was this that led to our inclusion in this particular issue."
Further details regarding the Company's business, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database.
About UV Flu Technologies, Inc. (OTCBB: UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector. The Company manufactures the ViraTech UV-400, which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria at rates exceeding 99.2% on a first-pass basis. The product also is highly effective in reducing odors and VOC's, or Volatile Organic Compounds, such as acetone, benzene and formaldehyde. ViraTech UV-400 is a Class II medical device and is available without a prescription.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Investor Information:
Geaux IR Services, Inc.Toll-Free: 1-888-355-8838investors@uvflutech.com
SOURCE: UV Flu Technologies, Inc.
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Connect with Investorideas.com - http://www.twitter.com/Investorideas Publish Your News - Send a release - http://www.investorideas.com/News-Upload/
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.aspInvestorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Investorideas.com - Biotech/Pharma Stock News; BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) Reaches Key LibiGel® Safety Study Enrollment Target
Investorideas.com - Biotech/Pharma Stock News; BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) Reaches Key LibiGel® Safety Study Enrollment Target
First Unblinded Statistical Analysis to be Conducted on 2,500 Women
LINCOLNSHIRE, Ill. - October 18, 2010 (Investorideas.com newswire) BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced enrollment of the 2,500th woman in the LibiGel (testosterone gel) Phase III cardiovascular and breast cancer safety study. This important enrollment milestone triggers the first unblinded statistical analysis of cardiovascular events by the independent Data Monitoring Committee (DMC), which coincides with their fourth unblinded review of all adverse events. LibiGel is being developed for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women, for which there is currently no FDA approved product. BioSante anticipates the submission of a new drug application (NDA) for LibiGel in 2011.
The DMC's unblinded statistical analysis will determine whether the current study enrollment of 2,500 is sufficient to prove statistically the relative safety of LibiGel compared to placebo after an average of 12 months of exposure is reached, or if enrollment will continue. To date, there have been only 14 adjudicated cardiovascular (CV) events, a rate of approximately 0.65 percent, and only seven diagnoses of breast cancer, a rate of approximately 0.32 percent, after approximately 2,300 women-years of exposure in the study. BioSante will remain blinded as to the distribution of the reported safety events between the active and placebo study arms.
If enrollment continues beyond 2,500 women, an additional unblinded statistical analysis will be conducted by the DMC each time a new cardiovascular event is adjudicated. At each of these analyses the trial potentially could be fully enrolled. If enrollment is not completed sooner, enrollment will continue until the study reaches its predetermined maximum of 4,000 women.
"This milestone gives BioSante our first opportunity potentially to declare completion of enrollment in the safety study," stated Michael Snabes, M.D., Ph.D., BioSante's senior vice president of medical affairs. "We have had an extremely low number of cardiovascular and breast cancer events to date, as well as three previous favorable DMC recommendations. We expect the study to demonstrate the safety of LibiGel in the treated population, regardless of whether the DMC stops enrollment at 2,500 women or we need to continue enrollment."
About the LibiGel Phase III Cardiovascular and Breast Cancer Safety Study
The Phase III LibiGel safety study is a randomized, double-blind, placebo-controlled, multi-center, cardiovascular (CV) events and breast cancer study that will enroll between 2,500 and 4,000 women. The study will continue for a total of five years, however, BioSante can use the safety study data as part of an NDA submission after an average of 12 month exposure to LibiGel or placebo. BioSante anticipates the submission of a new drug application (NDA) for LibiGel in 2011.
The LibiGel safety study is tracking a predefined list of CV events, in agreement with the FDA, including CV death, myocardial infarction and stroke in women 50 years of age or older and suffering from at least two CV risk factors including hypertension and diabetes. The objective of the safety study is to show the relative safety of testosterone compared to placebo in the number of CV events. The incidence of breast cancer also is being tracked over the course of the study.
About LibiGel®
LibiGel is a testosterone gel in Phase III clinical development for the treatment of women who suffer from female sexual dysfunction (FSD). The on-going Phase III efficacy trials are double-blind, placebo-controlled trials that will enroll up to approximately 500 surgically menopausal women each for a six-month clinical trial. The efficacy trials are being conducted under an FDA-approved special protocol assessment (SPA) agreement. LibiGel is absorbed quickly through the skin after a once-daily pea-sized application on the upper arm, delivering testosterone to the bloodstream evenly over time and in a non-invasive and painless manner.
In a Phase II trial, LibiGel significantly increased the number of satisfying sexual events in surgically menopausal women suffering from FSD by 238 percent versus baseline (p<0.0001); this increase also was significant versus placebo (p<0.05). In this study, the effective dose of LibiGel produced testosterone blood levels within the normal range for pre-menopausal women and had a safety profile similar to that observed in the placebo group. In addition, no serious adverse events and no discontinuations due to adverse events occurred in any subject receiving LibiGel. The Phase II clinical trial was a double-blind, placebo-controlled trial, conducted in the United States, in surgically menopausal women distressed by their low sexual desire and activity.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment, and Elestrin™ (estradiol gel) for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, which is marketed in the U.S. by Azur Pharma, BioSante's licensee. BioSante also is developing a portfolio of cancer vaccines (GVAX), three of which have been granted orphan drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is developing its calcium phosphate technology (CaP) for aesthetic medicine (BioLook™), among other uses, as well as seeking opportunities for its 2A/Furin and other technologies. Additional information is available online at: www.biosantepharma.com.
Forward-Looking Statements
To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante's plans, objectives, expectations and intentions with respect to future operations and products, the timing of anticipated regulatory submissions and other statements identified by words such as "will," "potential," "could," "can," "believe," "intends," "continue," "plans," "expects," "anticipates," "estimates," "may," other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante's licensees or sublicensees; the success of clinical testing; and BioSante's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact:
BioSante Pharmaceuticals
For Media:The Trout Group LLCTricia Swanson(646) 378-2953tswanson@troutgroup.com
or
For Investors:McKinney/ChicagoAlan Zachary(312) 944-6784 ext. 316azachary@mckinneychicago.com
Visit the BPAX showcase profile at Investorideas.com - http://www.investorideas.com/CO/BPAX/
Request News and Info on BPAX - http://www.investorideas.com/Resources/Newsletter.asp
Visit this company: www.biosantepharma.com
Disclosure, Disclaimer: BPAX is a paid advertising client on Investorideas.com.
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Connect with Investorideas.com - http://www.twitter.com/Investorideas Publish Your News - Send a release - http://www.investorideas.com/News-Upload/
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.aspInvestorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
First Unblinded Statistical Analysis to be Conducted on 2,500 Women
LINCOLNSHIRE, Ill. - October 18, 2010 (Investorideas.com newswire) BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced enrollment of the 2,500th woman in the LibiGel (testosterone gel) Phase III cardiovascular and breast cancer safety study. This important enrollment milestone triggers the first unblinded statistical analysis of cardiovascular events by the independent Data Monitoring Committee (DMC), which coincides with their fourth unblinded review of all adverse events. LibiGel is being developed for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women, for which there is currently no FDA approved product. BioSante anticipates the submission of a new drug application (NDA) for LibiGel in 2011.
The DMC's unblinded statistical analysis will determine whether the current study enrollment of 2,500 is sufficient to prove statistically the relative safety of LibiGel compared to placebo after an average of 12 months of exposure is reached, or if enrollment will continue. To date, there have been only 14 adjudicated cardiovascular (CV) events, a rate of approximately 0.65 percent, and only seven diagnoses of breast cancer, a rate of approximately 0.32 percent, after approximately 2,300 women-years of exposure in the study. BioSante will remain blinded as to the distribution of the reported safety events between the active and placebo study arms.
If enrollment continues beyond 2,500 women, an additional unblinded statistical analysis will be conducted by the DMC each time a new cardiovascular event is adjudicated. At each of these analyses the trial potentially could be fully enrolled. If enrollment is not completed sooner, enrollment will continue until the study reaches its predetermined maximum of 4,000 women.
"This milestone gives BioSante our first opportunity potentially to declare completion of enrollment in the safety study," stated Michael Snabes, M.D., Ph.D., BioSante's senior vice president of medical affairs. "We have had an extremely low number of cardiovascular and breast cancer events to date, as well as three previous favorable DMC recommendations. We expect the study to demonstrate the safety of LibiGel in the treated population, regardless of whether the DMC stops enrollment at 2,500 women or we need to continue enrollment."
About the LibiGel Phase III Cardiovascular and Breast Cancer Safety Study
The Phase III LibiGel safety study is a randomized, double-blind, placebo-controlled, multi-center, cardiovascular (CV) events and breast cancer study that will enroll between 2,500 and 4,000 women. The study will continue for a total of five years, however, BioSante can use the safety study data as part of an NDA submission after an average of 12 month exposure to LibiGel or placebo. BioSante anticipates the submission of a new drug application (NDA) for LibiGel in 2011.
The LibiGel safety study is tracking a predefined list of CV events, in agreement with the FDA, including CV death, myocardial infarction and stroke in women 50 years of age or older and suffering from at least two CV risk factors including hypertension and diabetes. The objective of the safety study is to show the relative safety of testosterone compared to placebo in the number of CV events. The incidence of breast cancer also is being tracked over the course of the study.
About LibiGel®
LibiGel is a testosterone gel in Phase III clinical development for the treatment of women who suffer from female sexual dysfunction (FSD). The on-going Phase III efficacy trials are double-blind, placebo-controlled trials that will enroll up to approximately 500 surgically menopausal women each for a six-month clinical trial. The efficacy trials are being conducted under an FDA-approved special protocol assessment (SPA) agreement. LibiGel is absorbed quickly through the skin after a once-daily pea-sized application on the upper arm, delivering testosterone to the bloodstream evenly over time and in a non-invasive and painless manner.
In a Phase II trial, LibiGel significantly increased the number of satisfying sexual events in surgically menopausal women suffering from FSD by 238 percent versus baseline (p<0.0001); this increase also was significant versus placebo (p<0.05). In this study, the effective dose of LibiGel produced testosterone blood levels within the normal range for pre-menopausal women and had a safety profile similar to that observed in the placebo group. In addition, no serious adverse events and no discontinuations due to adverse events occurred in any subject receiving LibiGel. The Phase II clinical trial was a double-blind, placebo-controlled trial, conducted in the United States, in surgically menopausal women distressed by their low sexual desire and activity.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment, and Elestrin™ (estradiol gel) for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, which is marketed in the U.S. by Azur Pharma, BioSante's licensee. BioSante also is developing a portfolio of cancer vaccines (GVAX), three of which have been granted orphan drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is developing its calcium phosphate technology (CaP) for aesthetic medicine (BioLook™), among other uses, as well as seeking opportunities for its 2A/Furin and other technologies. Additional information is available online at: www.biosantepharma.com.
Forward-Looking Statements
To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante's plans, objectives, expectations and intentions with respect to future operations and products, the timing of anticipated regulatory submissions and other statements identified by words such as "will," "potential," "could," "can," "believe," "intends," "continue," "plans," "expects," "anticipates," "estimates," "may," other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante's licensees or sublicensees; the success of clinical testing; and BioSante's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact:
BioSante Pharmaceuticals
For Media:The Trout Group LLCTricia Swanson(646) 378-2953tswanson@troutgroup.com
or
For Investors:McKinney/ChicagoAlan Zachary(312) 944-6784 ext. 316azachary@mckinneychicago.com
Visit the BPAX showcase profile at Investorideas.com - http://www.investorideas.com/CO/BPAX/
Request News and Info on BPAX - http://www.investorideas.com/Resources/Newsletter.asp
Visit this company: www.biosantepharma.com
Disclosure, Disclaimer: BPAX is a paid advertising client on Investorideas.com.
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Connect with Investorideas.com - http://www.twitter.com/Investorideas Publish Your News - Send a release - http://www.investorideas.com/News-Upload/
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.aspInvestorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Investorideas.com - Biotech/Pharma Stock News; UV Flu Technologies (OTCBB: UVFT) Selected for Second Profile in Influential UK-Based Public Service Review, as Outbreak of Legionnaires Disease Draws Renewed Attention to Dangers of Airborne Bacteria
Investorideas.com - Biotech/Pharma Stock News; UV Flu Technologies (OTCBB: UVFT) Selected for Second Profile in Influential UK-Based Public Service Review, as Outbreak of Legionnaires Disease Draws Renewed Attention to Dangers of Airborne Bacteria
CENTERVILLE, MA - October 18, 2010 (Investorideas.com newswire) UV Flu Technologies, Inc. (OTC.BB:UVFT) is pleased to announce that it has been selected as the only air purification medical device to be listed in the Infection Control Segment of the prestigious UK-based opinion and analysis industry publication "Public Service Review." In this, our second appearance for 2010, the Company offers an informative profile within the magazine as well as a full page back cover advertisement.
The Public Service Review features contributors that include UK and foreign ministers, senior civil servants, experts and academics discussing the latest initiatives and projects along with case studies and comments on best practices affecting public sector initiatives worldwide.
"The spread of airborne bacteria and infectious diseases in the United Kingdom, in some areas, is reaching epidemic levels," said Jack Lennon, President of UV Flu Technologies. "There is more than a 10% risk of becoming infected by HAI's, or hospital associated infections, in many of the medical facilities in the United Kingdom, making Infection Control a much more visible issue than it is in this country. Being selected for inclusion by the 'Review' as the only laboratory tested device capable of killing these bacterial superbugs is a distinct honor."
Mr. Lennon continued to say, "There is a great deal of attention in the UK, and in the United States, on the spread of MRSA, a bacteria resistant to antibiotics and estimated to kill tens of thousands of people every year, and in many instances affects people who have been in a medical facility. In fact, over the last 4 weeks an outbreak of Legionnaires Disease in South Wales garnered international attention as three deaths were reported, and a number of people were stricken. The world believed Legionnaires to no longer pose a threat, but experts believe it kills thousands of people yearly through improper diagnosis as pneumonia. The ViraTech UV-400 cost effectively and efficiently kills these airborne bacterial strains, and it was this that led to our inclusion in this particular issue."
Further details regarding the Company's business, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database.
About UV Flu Technologies, Inc. (OTC.BB:UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector. The Company manufactures the ViraTech UV-400, which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria at rates exceeding 99.2% on a first-pass basis. The product also is highly effective in reducing odors and VOC's, or Volatile Organic Compounds, such as acetone, benzene and formaldehyde. ViraTech UV-400 is a Class II medical device and is available without a prescription.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Contact:
Investor Information:Geaux IR Services, Inc.Toll-Free: 1-888-355-8838investors@uvflutech.com
Visit the UVFT showcase profile at Investorideas.com: http://www.investorideas.com/CO/UVFT/ Request News and Info on UVFT: http://www.investorideas.com/Resources/Newsletter.asp
Visit this company: www.uvflutech.com
Disclosure, Disclaimer/ UVFT is a paid advertising client on Investorideas.com.
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Connect with Investorideas.com - http://www.twitter.com/Investorideas Publish Your News - Send a release - http://www.investorideas.com/News-Upload/
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.aspInvestorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
CENTERVILLE, MA - October 18, 2010 (Investorideas.com newswire) UV Flu Technologies, Inc. (OTC.BB:UVFT) is pleased to announce that it has been selected as the only air purification medical device to be listed in the Infection Control Segment of the prestigious UK-based opinion and analysis industry publication "Public Service Review." In this, our second appearance for 2010, the Company offers an informative profile within the magazine as well as a full page back cover advertisement.
The Public Service Review features contributors that include UK and foreign ministers, senior civil servants, experts and academics discussing the latest initiatives and projects along with case studies and comments on best practices affecting public sector initiatives worldwide.
"The spread of airborne bacteria and infectious diseases in the United Kingdom, in some areas, is reaching epidemic levels," said Jack Lennon, President of UV Flu Technologies. "There is more than a 10% risk of becoming infected by HAI's, or hospital associated infections, in many of the medical facilities in the United Kingdom, making Infection Control a much more visible issue than it is in this country. Being selected for inclusion by the 'Review' as the only laboratory tested device capable of killing these bacterial superbugs is a distinct honor."
Mr. Lennon continued to say, "There is a great deal of attention in the UK, and in the United States, on the spread of MRSA, a bacteria resistant to antibiotics and estimated to kill tens of thousands of people every year, and in many instances affects people who have been in a medical facility. In fact, over the last 4 weeks an outbreak of Legionnaires Disease in South Wales garnered international attention as three deaths were reported, and a number of people were stricken. The world believed Legionnaires to no longer pose a threat, but experts believe it kills thousands of people yearly through improper diagnosis as pneumonia. The ViraTech UV-400 cost effectively and efficiently kills these airborne bacterial strains, and it was this that led to our inclusion in this particular issue."
Further details regarding the Company's business, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database.
About UV Flu Technologies, Inc. (OTC.BB:UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector. The Company manufactures the ViraTech UV-400, which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria at rates exceeding 99.2% on a first-pass basis. The product also is highly effective in reducing odors and VOC's, or Volatile Organic Compounds, such as acetone, benzene and formaldehyde. ViraTech UV-400 is a Class II medical device and is available without a prescription.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Contact:
Investor Information:Geaux IR Services, Inc.Toll-Free: 1-888-355-8838investors@uvflutech.com
Visit the UVFT showcase profile at Investorideas.com: http://www.investorideas.com/CO/UVFT/ Request News and Info on UVFT: http://www.investorideas.com/Resources/Newsletter.asp
Visit this company: www.uvflutech.com
Disclosure, Disclaimer/ UVFT is a paid advertising client on Investorideas.com.
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Connect with Investorideas.com - http://www.twitter.com/Investorideas Publish Your News - Send a release - http://www.investorideas.com/News-Upload/
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.aspInvestorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Subscribe to:
Posts (Atom)